Oxidative stress in fibromyalgia: Pathophysiology and clinical implications.;Estrés oxidativo en la fibromialgia: Fisiopatología e implicaciones clínicas

Reumatologia Clinica

Volumn 7, Issue 5, 2011, Pages 281-283

  Cordero, Mario D ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; GINKGO BILOBA EXTRACT; GLUTATHIONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELATONIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RETINOL; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE;

ANTIOXIDANT ACTIVITY; BIOSYNTHESIS; CYTOKINE PRODUCTION; DEFENSE MECHANISM; DRUG MECHANISM; EDITORIAL; FIBROMYALGIA; HUMAN; LIPID PEROXIDATION; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RESPIRATORY CHAIN;

EID: 80052963983     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2010.12.007     Document Type: Article

References (23)

1. Davies K.J. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp. 1995, 61:1-31.
2. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007, 39:44-84.
3. Rivera J., Alegre C., Ballina F.J., Carbonell J., Carmona L., Castel B., et al. Documento de consenso de la Sociedad Española de Reumatología sobre la fibromialgia. Reumatol Clin. 2006, 2:S55-S66.
4. Ozgocmen S., Ozyurt H., Sogut S., Akyol O., Ardicoglu O., Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int. 2006, 26:598-603.
5. Altindag O., Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep. 2006, 11:131-135.
6. Sendur O.F., Turan Y., Tastaban E., Yenisey C., Serter M. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int. 2009, 29:629-633.
7. Cordero M.D., De Miguel M., Moreno Fernández A.M., Carmona López I.M., Garrido Maraver J., Cotán D., et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther. 2010, 12:R17.
8. Cordero MD, de Miguel M, Moreno-Fernández AM. Mitochondrial dysfunction in fibromyalgia and its implication in the pathogenesis of disease. Med Clin (Barc). 2010 Apr 24 [Epub ahead of print].
9. Menzies V., Lyon D.E. Integrated review of the association of cytokines with fibromyalgia and fibromyalgia core symptoms. Biol Res Nurs. 2010, 11:387-394.
10. Fulle S., Mecocci P., Fano G., Vecchiet I., Vecchini A., Racciotti D., et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med. 2000, 29:1252-1259.
11. Lister R.E. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res. 2002, 30:195-199.
12. Fu X., Ji R., Dam J. Antifatigue effect of coenzyme Q10 in mice. J Med Food. 2010, 13:211-215.
13. Mizuno K., Tanaka M., Nozaki S., Mizuma H., Ataka S., Tahara T., et al. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition. 2008, 24:293-299.
14. Caso G., Kelly P., McNurlan M.A., Lawson W.E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007, 99:1409-1412.
15. Jung H.J., Park E.H., Lim C.J. Evaluation of anti-angiogenic, anti-inflammatory and antinociceptive activity of coenzyme Q(10) in experimental animals. J Pharm Pharmacol. 2009, 61:1391-1395.
16. Schmelzer C., Lindner I., Rimbach G., Niklowitz P., Menke T., Döring F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors. 2008, 32:179-183.
17. Reiter R.J., Acuna-Castroviejo D., Tan D.X. Melatonin therapy in fibromyalgia. Curr Pain Headache Rep. 2007, 11:339-342.
18. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002, 59:1541-1550. Parkinson Study Group.
19. Gutzmann H., Kühl K.P., Hadler D., Rapp M.A. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry. 2002, 35:12-18.
20. Cooper J.M., Korlipara L.V., Hart P.E., Bradley J.L., Schapira A.H. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008, 15:1371-1379.
21. Sandor P.S., Di Clemente L., Coppola G., Saenger U., Fumal A., Magis D., et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005, 64:713-715.
22. Montini G., Malaventura C., Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med. 2008, 358:2849-2850.
23. Keogh A., Fenton S., Leslie C., Aboyoun C., Macdonald P., Zhao Y.C., et al. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ. 2003, 12:135-141.